Literature DB >> 27683557

TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer.

Benjamin V Park1,2, Zachary T Freeman1, Ali Ghasemzadeh2, Michael A Chattergoon1, Alleluiah Rutebemberwa1, Jordana Steigner1, Matthew E Winter1, Thanh V Huynh3, Suzanne M Sebald3, Se-Jin Lee3, Fan Pan2, Drew M Pardoll2, Andrea L Cox4,2.   

Abstract

Programmed death-1 (PD-1) is a coinhibitory receptor that downregulates the activity of tumor-infiltrating lymphocytes (TIL) in cancer and of virus-specific T cells in chronic infection. The molecular mechanisms driving high PD-1 expression on TILs have not been fully investigated. We demonstrate that TGFβ1 enhances antigen-induced PD-1 expression through SMAD3-dependent, SMAD2-independent transcriptional activation in T cells in vitro and in TILs in vivo The PD-1hi subset seen in CD8+ TILs is absent in Smad3-deficient tumor-specific CD8+ TILs, resulting in enhanced cytokine production by TILs and in draining lymph nodes and antitumor activity. In addition to TGFβ1's previously known effects on T-cell function, our findings suggest that TGFβ1 mediates T-cell suppression via PD-1 upregulation in the tumor microenvironment (TME). They highlight bidirectional cross-talk between effector TILs and TGFβ-producing cells that upregulates multiple components of the PD-1 signaling pathway to inhibit antitumor immunity. SIGNIFICANCE: Engagement of the coinhibitory receptor PD-1 or its ligand, PD-L1, dramatically inhibits the antitumor function of TILs within the TME. Our findings represent a novel immunosuppressive function of TGFβ and demonstrate that TGFβ1 allows tumors to evade host immune responses in part through enhanced SMAD3-mediated PD-1 expression on TILs. Cancer Discov; 6(12); 1366-81. ©2016 AACRThis article is highlighted in the In This Issue feature, p. 1293. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27683557      PMCID: PMC5295786          DOI: 10.1158/2159-8290.CD-15-1347

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  69 in total

Review 1.  Mechanisms of TGF-beta signaling from cell membrane to the nucleus.

Authors:  Yigong Shi; Joan Massagué
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

2.  T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine.

Authors:  Moses K Donkor; Abira Sarkar; Peter A Savage; Ruth A Franklin; Linda K Johnson; Achim A Jungbluth; James P Allison; Ming O Li
Journal:  Immunity       Date:  2011-07-14       Impact factor: 31.745

3.  An elevated serum level of transforming growth factor-beta 1 (TGF-beta 1) significantly correlated with lymph node metastasis and poor prognosis in patients with gastric carcinoma.

Authors:  H Saito; S Tsujitani; S Oka; A Kondo; M Ikeguchi; M Maeta; N Kaibara
Journal:  Anticancer Res       Date:  2000 Nov-Dec       Impact factor: 2.480

4.  TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance.

Authors:  Dori A Thomas; Joan Massagué
Journal:  Cancer Cell       Date:  2005-11       Impact factor: 31.743

5.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

6.  Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.

Authors:  Y Agata; A Kawasaki; H Nishimura; Y Ishida; T Tsubata; H Yagita; T Honjo
Journal:  Int Immunol       Date:  1996-05       Impact factor: 4.823

7.  Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

Authors:  R Houston Thompson; Susan M Kuntz; Bradley C Leibovich; Haidong Dong; Christine M Lohse; W Scott Webster; Shomik Sengupta; Igor Frank; Alexander S Parker; Horst Zincke; Michael L Blute; Thomas J Sebo; John C Cheville; Eugene D Kwon
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

8.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

Authors:  Mojgan Ahmadzadeh; Laura A Johnson; Bianca Heemskerk; John R Wunderlich; Mark E Dudley; Donald E White; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

9.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

10.  Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells.

Authors:  Hendrik Streeck; Zabrina L Brumme; Michael Anastario; Kristin W Cohen; Jonathan S Jolin; Angela Meier; Chanson J Brumme; Eric S Rosenberg; Galit Alter; Todd M Allen; Bruce D Walker; Marcus Altfeld
Journal:  PLoS Med       Date:  2008-05-06       Impact factor: 11.069

View more
  90 in total

Review 1.  TGFβ biology in cancer progression and immunotherapy.

Authors:  Rik Derynck; Shannon J Turley; Rosemary J Akhurst
Journal:  Nat Rev Clin Oncol       Date:  2020-07-24       Impact factor: 66.675

2.  Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy.

Authors:  Masaki Terabe; Faith C Robertson; Katharine Clark; Emma De Ravin; Anja Bloom; David J Venzon; Shingo Kato; Amer Mirza; Jay A Berzofsky
Journal:  Oncoimmunology       Date:  2017-03-31       Impact factor: 8.110

3.  PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer.

Authors:  Ozlen Saglam; Jose Conejo-Garcia
Journal:  Integr Cancer Sci Ther       Date:  2018-04-14

4.  SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells.

Authors:  Tom L Stephen; Kyle K Payne; Ricardo A Chaurio; Michael J Allegrezza; Hengrui Zhu; Jairo Perez-Sanz; Alfredo Perales-Puchalt; Jenny M Nguyen; Ana E Vara-Ailor; Evgeniy B Eruslanov; Mark E Borowsky; Rugang Zhang; Terri M Laufer; Jose R Conejo-Garcia
Journal:  Immunity       Date:  2017-01-17       Impact factor: 31.745

Review 5.  The role of TGF-beta signaling in dendritic cell tolerance.

Authors:  Grace E Esebanmen; William H R Langridge
Journal:  Immunol Res       Date:  2017-10       Impact factor: 2.829

Review 6.  Cancer-associated fibroblasts: how do they contribute to metastasis?

Authors:  Mei Qi Kwa; Kate M Herum; Cord Brakebusch
Journal:  Clin Exp Metastasis       Date:  2019-03-07       Impact factor: 5.150

Review 7.  Tumor Plasticity and Resistance to Immunotherapy.

Authors:  Lucas A Horn; Kristen Fousek; Claudia Palena
Journal:  Trends Cancer       Date:  2020-03-04

8.  Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment.

Authors:  Xingzhe Ma; Enguang Bi; Yong Lu; Pan Su; Chunjian Huang; Lintao Liu; Qiang Wang; Maojie Yang; Matthew F Kalady; Jianfei Qian; Aijun Zhang; Anisha A Gupte; Dale J Hamilton; Chengyun Zheng; Qing Yi
Journal:  Cell Metab       Date:  2019-04-25       Impact factor: 27.287

Review 9.  Multidimensional communication in the microenvirons of glioblastoma.

Authors:  Marike L Broekman; Sybren L N Maas; Erik R Abels; Thorsten R Mempel; Anna M Krichevsky; Xandra O Breakefield
Journal:  Nat Rev Neurol       Date:  2018-08       Impact factor: 42.937

10.  YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity.

Authors:  Xuhao Ni; Jinhui Tao; Joseph Barbi; Qian Chen; Benjamin V Park; Zhiguang Li; Nailing Zhang; Andriana Lebid; Anjali Ramaswamy; Ping Wei; Ying Zheng; Xuehong Zhang; Xingmei Wu; Paolo Vignali; Cui-Ping Yang; Huabin Li; Drew Pardoll; Ling Lu; Duojia Pan; Fan Pan
Journal:  Cancer Discov       Date:  2018-06-15       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.